Published in World J Gastroenterol on June 01, 2003
Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol (2004) 1.70
RERG suppresses cell proliferation, migration and angiogenesis through ERK/NF-κB signaling pathway in nasopharyngeal carcinoma. J Exp Clin Cancer Res (2017) 1.41
Inorganic nanoparticles in cancer therapy. Pharm Res (2010) 1.11
Tumour Angiogenesis and Angiogenic Inhibitors: A Review. J Clin Diagn Res (2015) 1.09
Reduction of metastatic and angiogenic potency of malignant cancer by Eupatorium fortunei via suppression of MMP-9 activity and VEGF production. Sci Rep (2014) 1.01
Microvascular endothelial cells of the corpus luteum. Reprod Biol Endocrinol (2003) 0.99
Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease. J Cell Mol Med (2008) 0.97
MicroRNAs: promising new antiangiogenic targets in cancer. Biomed Res Int (2014) 0.91
Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis. World J Gastroenterol (2004) 0.89
Angiogenesis in salivary carcinomas with and without myoepithelial differentiation. Virchows Arch (2008) 0.89
alpha1-antitrypsin and its C-terminal fragment attenuate effects of degranulated neutrophil-conditioned medium on lung cancer HCC cells, in vitro. Cancer Cell Int (2004) 0.87
Expression of vascular endothelial growth factor and microvessel density in oral tumorigenesis. J Oral Maxillofac Pathol (2012) 0.86
Cyclooxygenase-2 up-regulates vascular endothelial growth factor via a protein kinase C pathway in non-small cell lung cancer. J Exp Clin Cancer Res (2011) 0.86
Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors. Nucl Med Biol (2012) 0.86
Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Chin J Cancer Res (2012) 0.86
Vascular endothelial growth factor-A and changes in a tumor-bearing mouse model with Lewis lung cancer. Oncol Lett (2011) 0.85
Lung tumorigenesis induced by human vascular endothelial growth factor (hVEGF)-A165 overexpression in transgenic mice and amelioration of tumor formation by miR-16. Oncotarget (2015) 0.84
Diagnosis of solid breast tumors using vessel analysis in three-dimensional power Doppler ultrasound images. J Digit Imaging (2013) 0.84
Impact of breast cancer surgery on angiogenesis circulating biomarkers: a prospective longitudinal study. World J Surg Oncol (2013) 0.81
Aminoguanidine impedes human pancreatic tumor growth and metastasis development in nude mice. World J Gastroenterol (2009) 0.80
Antiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: Inhibition of vascular endothelial growth factor and matrix metalloproteinase-2 expression in vitro. World J Gastroenterol (2004) 0.80
Alteration of somatostatin receptor subtype 2 gene expression in pancreatic tumor angiogenesis. World J Gastroenterol (2004) 0.80
Melatonin inhibits the expression of vascular endothelial growth factor in pancreatic cancer cells. Chin J Cancer Res (2012) 0.80
Anti-neoplastic efficacy of Haimiding on gastric carcinoma and its mechanisms. World J Gastroenterol (2004) 0.80
Roles of main pro- and anti-angiogenic factors in tumor angiogenesis. World J Gastroenterol (2004) 0.79
Anti-tumor activity of Eurycoma longifolia root extracts against K-562 cell line: in vitro and in vivo study. PLoS One (2014) 0.79
Enhancement of migration and invasion of hepatoma cells via a Rho GTPase signaling pathway. World J Gastroenterol (2004) 0.79
The synergistic inhibitory effect of somatostatin-doxorubicin co-treatment on gallbladder carcinoma. BMC Cancer (2007) 0.78
Anti-angiogenic effects of differentiation-inducing factor-1 involving VEGFR-2 expression inhibition independent of the Wnt/β-catenin signaling pathway. Mol Cancer (2010) 0.78
A framework to identify gene expression profiles in a model of inflammation induced by lipopolysaccharide after treatment with thalidomide. BMC Res Notes (2012) 0.77
Immunohistochemical study of vascular endothelial growth factor (VEGF), tumor suppressor protein (p53) and intercellular adhesion molecule (ICAM-1) in the conjunctiva of diabetic patients. J Mol Histol (2006) 0.77
Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model. World J Gastroenterol (2004) 0.77
Immunotherapy of hepatoma with a monoclonal antibody against murine endoglin. World J Gastroenterol (2007) 0.77
Relationship between inducible nitric oxide synthase expression and angiogenesis in primary gallbladder carcinoma tissue. World J Gastroenterol (2004) 0.77
Thy-1-induced migration inhibition in vascular endothelial cells through reducing the RhoA activity. PLoS One (2013) 0.75
Zingerone suppresses angiogenesis via inhibition of matrix metalloproteinases during tumor development. Oncotarget (2016) 0.75
Anti-cancer activities of Brassica juncea leaves in vitro. EXCLI J (2016) 0.75
Ethanol extract of Lophatheri Herba exhibits anti-cancer activity in human cancer cells by suppression of metastatic and angiogenic potential. Sci Rep (2016) 0.75
Alphastatin downregulates vascular endothelial cells sphingosine kinase activity and suppresses tumor growth in nude mice bearing human gastric cancer xenografts. World J Gastroenterol (2006) 0.75
Comparison of the blood and lymphatic microvessel density of pleomorphic adenoma and Basal cell adenoma. Clin Med Insights Pathol (2015) 0.75
A novel regulator of angiogenesis in endothelial cells: 5-hydroxytriptamine 4 receptor. Angiogenesis (2012) 0.75
Honey and Cancer: Current Status and Future Directions. Diseases (2016) 0.75
Cancer cell cycles. Science (1996) 21.29
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
Mechanisms of angiogenesis and arteriogenesis. Nat Med (2000) 13.88
Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature (1999) 13.73
Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature (1999) 11.37
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (1991) 9.21
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem (1998) 8.30
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev (2000) 8.24
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 7.66
Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51
Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (1994) 5.54
Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res (1977) 5.19
Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med (2000) 5.05
Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway. Circ Res (2000) 4.97
The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem (1995) 4.77
Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol (1988) 4.34
Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol (1997) 4.09
Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol (2001) 3.84
Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol (1990) 3.81
Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci (1998) 3.80
Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem (1998) 3.78
Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem (1999) 3.76
Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation. Mol Biol Cell (1996) 3.60
Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A (2000) 3.40
Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol (2002) 3.36
Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem (2000) 3.30
Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A (2002) 3.25
Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell (1998) 2.89
Conversion of a high molecular weight latent beta-TGF from chicken embryo fibroblasts into a low molecular weight active beta-TGF under acidic conditions. Biochem Biophys Res Commun (1985) 2.75
Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol (1988) 2.69
Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol (1990) 2.65
Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int J Cancer (2000) 2.64
Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev (1998) 2.55
Endostatin induces endothelial cell apoptosis. J Biol Chem (1999) 2.49
Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol (1996) 2.42
Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res (1999) 2.39
Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. Circ Res (2000) 2.39
Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc Natl Acad Sci U S A (1997) 2.32
Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun (1991) 2.25
Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist (2001) 2.22
The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev (1991) 2.20
Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A (2001) 2.19
Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia. Circulation (1995) 2.18
Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol (1992) 2.14
Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci U S A (1996) 2.12
Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest (1998) 2.02
Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene (1994) 2.01
Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol (1990) 2.00
Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem (2002) 1.98
Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett (2000) 1.97
Akt takes center stage in angiogenesis signaling. Circ Res (2000) 1.96
Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A (1999) 1.95
Molecular mechanisms of blood vessel formation. Trends Biochem Sci (1997) 1.93
VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res (1999) 1.91
Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol (1993) 1.88
Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem (1997) 1.86
Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci U S A (2001) 1.83
Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J Biol Chem (1998) 1.80
Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology (1999) 1.70
Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res (2000) 1.70
Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol (2000) 1.68
A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci U S A (1998) 1.66
Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem (1996) 1.63
Akt is more than just a Bad kinase. Nature (1999) 1.60
Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging (2002) 1.59
TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer (1998) 1.58
Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. Lab Invest (1992) 1.57
Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion. Circ Res (2000) 1.57
Inhibition of angiogenesis by interleukin 4. J Exp Med (1998) 1.53
Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst (2002) 1.52
Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood (2000) 1.45
VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathways. Microvasc Res (2001) 1.45
Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett (1997) 1.45
TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine (1997) 1.42
Retracted Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. J Biol Chem (2002) 1.40
Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas (2003) 1.40
Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med (2000) 1.39
Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev (1995) 1.39
Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res (1996) 1.38
Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci (1997) 1.38
Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci U S A (1998) 1.37
A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis (2002) 1.37
Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci U S A (1995) 1.35
Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J (1995) 1.34
Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem (1995) 1.34
Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood (1998) 1.32
Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J (1998) 1.31
Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol (1996) 1.30
Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res (2000) 1.30
Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res (1999) 1.28
Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice. Br J Cancer (1999) 1.26
The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J (2002) 1.26
TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer (2001) 1.24
Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J (2002) 1.22
Cox-2, iNOS and p53 as play-makers of tumor angiogenesis (review). Int J Mol Med (1998) 1.21
Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res (1998) 1.19
siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity. Dig Dis Sci (2008) 1.02
Influence of splanchnic vascular infusion on the content of endotoxins in plasma and the translocation of intestinal bacteria in rats with acute hemorrhage necrosis pancreatitis. World J Gastroenterol (2000) 0.99
Expression of TREM-1 mRNA in acute pancreatitis. World J Gastroenterol (2004) 0.99
CD133(+) gallbladder carcinoma cells exhibit self-renewal ability and tumorigenicity. World J Gastroenterol (2011) 0.92
Anti-angiogenic effects of somatostatin receptor subtype 2 on human pancreatic cancer xenografts. Carcinogenesis (2004) 0.92
Experimental research on production and uptake sites of TNFalpha in rats with acute hemorrhagic necrotic pancreatitis. World J Gastroenterol (1998) 0.87
Proteome analysis of human pancreatic ductal adenocarcinoma tissue using two-dimensional gel electrophoresis and tandem mass spectrometry for identification of disease-related proteins. Dig Dis Sci (2007) 0.86
Reversal of the phenotype by K-rasval12 silencing mediated by adenovirus-delivered siRNA in human pancreatic cancer cell line Panc-1. World J Gastroenterol (2005) 0.84
Mechanisms of inhibition of growth of human pancreatic carcinoma implanted in nude mice by somatostatin receptor subtype 2. Pancreas (2004) 0.83
Gene transfer of somatostatin receptor type 2 by intratumoral injection inhibits established pancreatic carcinoma xenografts. World J Gastroenterol (2005) 0.82
Association between serotonin transporter (SERT) gene polymorphism and idiopathic pulmonary arterial hypertension: a meta-analysis and review of the literature. Metabolism (2013) 0.81
Circulating myeloid-derived suppressor cells in patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int (2016) 0.80
Antiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: Inhibition of vascular endothelial growth factor and matrix metalloproteinase-2 expression in vitro. World J Gastroenterol (2004) 0.80
Survivin expression induced by doxorubicin in cholangiocarcinoma. World J Gastroenterol (2004) 0.78
Effect of octreotide on human pancreatic cancer cells after transfected with somatostatin receptor type 2 gene. World J Gastroenterol (2004) 0.75
A new approach for Roux-en-Y reconstruction after pancreaticoduodenectomy. Hepatobiliary Pancreat Dis Int (2014) 0.75
Pancreaticoduodenectomy for borderline resectable pancreatic head cancer with a modified artery-first approach technique. Hepatobiliary Pancreat Dis Int (2017) 0.75